Medicare Benefits Schedule - Note PN.7.19

PBS restrictions for PARP inhibitors for a patient with homologous recombination deficiency (HRD) may include:

HRD positivity is considered to be a score of 42 or greater using the Myriad MyChoice HRD assay or a validated equivalent.

Related Items: 73307

• Previous - Note PN.7.18
• Next - Note PN.7.20

A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is:

(a)    to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and

(b)    including a service described in item 73301

Applicable once per primary tumour diagnosis

Fee: $3,000.00 Benefit: 75% = $2,250.00 85% = $2,895.50

(See para PN.7.19 of explanatory notes to this Category)